GlassScriptPhysician profile
Arun Kapur
NPI 1265850242
$1,856.25
in general payments reported to CMS, 2019-2025
26 companies · $20.26 in 2025
The $20.26 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $782 · 2021: $17.63 · 2022: $46.24 · 2023: $392 · 2024: $598 · 2025: $20.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,010.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $473.31 | 2019-2024 | Fasenra, Farxiga, Breztri |
| Novo Nordisk INC | $417.33 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $134.58 | 2019-2025 | |
| Amgen INC. | $120.62 | 2019-2024 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $84.11 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.50 | 2019 | |
| Sanofi-Aventis U.S. LLC | $63.02 | 2019 | |
| Abbott Laboratories | $60.88 | 2022-2023 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $60.09 | 2019-2023 | |
| Astellas Pharma US INC | $54.72 | 2019 | |
| Janssen Pharmaceuticals, INC | $34.73 | 2019-2021 | |
| Vivus LLC | $33.91 | 2023-2024 | Qsymia |
| Lilly USA, LLC | $33.37 | 2019 | |
| Shire North American Group INC | $31.89 | 2019 | |
| Mayne Pharma Commercial LLC | $22.20 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $21.81 | 2019 | |
| Sanofi Pasteur INC. | $20.68 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $17.04 | 2024 | Uptravi, Opsumit |
| Dynavax Technologies Corporation | $15.80 | 2024 | Heplisav-B |
| Merck Sharp & Dohme LLC | $14.46 | 2019 | |
| Inari Medical, INC. | $13.37 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Exact Sciences Corporation | $13.32 | 2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.08 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.71 | 2023 | Seglentis |
| E.R. Squibb & Sons, L.L.C. | $11.72 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Kapur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.